European Commission approves Epidyolex for the treatment of seizures associated with tuberous sclerosis complex – GW Pharma/Jazz Pharma
GW Pharmaceuticals plc announced that the European Commission (EC) has approved the Type II variation application for Epidyolex (cannabidiol) as an adjunctive treatment of seizures associated with TSC,… read more.
